[2026 update] Distinguishing expected GI effects from something that needs urgent attention

On the subject in the title: Distinguishing expected GI effects from something that needs urgent attention Working notes rather than a conclusion.

Reporting something rather than asking about it, in case the pattern is useful to anyone else.

Over 20 weeks I logged this consistently: date, dose, time of day, and a simple severity score from 0 to 4 for each symptom. That is 82 data points, all self-reported, all unblinded, and collected by someone who knew what he expected to find. Treat it accordingly.

The reason I am posting is that my experience does not match the shape people usually describe here, and I would like to know whether that is unusual or whether the usual description is just the loudest version.

Discontinuation for adverse effects in the published trials was not rare at the higher doses. That number belongs in any discussion of tolerability and is usually left out.

That has held every time I have looked, which is not the same as always.

The arithmetic in post #2 is right; the assumption feeding it is the part to check.

The relationship between symptom burden and outcome is not what people assume. Feeling worse is not evidence of a larger effect and feeling nothing is not evidence of an inactive preparation.

Answering the question the opening post raises rather than the one it answers.

The published rates come from populations that were titrated on a defined schedule with clinical supervision. Rates from a forum are not comparable and are biased by who chooses to post.

Taking post #2 at face value and following it one step further.

Reflux and eructation are the two most under-reported effects in the first-hand accounts here, and both follow directly from delayed emptying.

The published rates come from populations that were titrated on a defined schedule with clinical supervision. Rates from a forum are not comparable and are biased by who chooses to post.

Same conclusion as the reply above, reached differently, which is mildly reassuring.

Injection-site reactions are usually local, brief and unremarkable. A reaction spreading over a day, or accompanied by systemic symptoms, is a different thing and needs a clinician.

That holds under the stated conditions and I have stated them.

Right — I had this wrong and I am glad to have read it before it mattered.

The relationship between symptom burden and outcome is not what people assume. Feeling worse is not evidence of a larger effect and feeling nothing is not evidence of an inactive preparation.

I had written a reply contradicting post #9 and deleted it. Here is what survived.

Vomiting: when it is expected (first-dose reactions or early titration) and when it is a reason to stop and seek help are different. Occasional vomiting during titration is ordinary. Persistent vomiting or vomiting of a new character later in treatment warrants contact with your clinician.

Gastrointestinal effects in this class are dose-related and escalation-related. Both are true simultaneously, which is why symptoms typically return at each step and then settle again.

Speaking for myself and not for anyone else who has posted here.

Effects that improve with time and effects that improve with dose reduction are different findings. Working out which you have requires holding the dose steady long enough to see.

Not the whole picture, but the part of it I can speak to.

Worth separating two things that post #11 runs together.

The published rates come from populations that were titrated on a defined schedule with clinical supervision. Rates from a forum are not comparable and are biased by who chooses to post.

Fair, and the limits you put on it are the part I will remember.